Tango Therapeutics (TNGX) 44th Annual J.P. Morgan Healthcare Conference summary

Leadership transition and strategic direction

• Malte Peters, MD, appointed CEO, brings extensive late-stage development and regulatory experience from MorphoSys, Sandoz, and Novartis Oncology, ensuring continuity as he has been involved since 2018.

• Leadership change aligns with the shift from early development to late-phase drug development and regulatory focus, aiming to drive the next phase of growth with innovative combination regimens.

• Smooth transition ensured by Peters' familiarity with the board, executive team, and ongoing projects.

• No major strategic changes expected due to Peters' prior involvement in shaping current direction.

Pipeline highlights and clinical progress

• Pipeline targets MTAP-deleted cancers, with TNG462 (vopimetostat) in dose expansion and combination studies, TNG908/TNG456 for brain-penetrant activity, and TNG961 as an IND-ready HBS1L degrader.

• Vopimetostat/TNG462 shows 27% response rate and 6.4 months median progression-free survival in monotherapy, with a pivotal trial in second-line pancreatic cancer planned for 2024/2026.

• In a histology-selective cohort, vopimetostat/TNG462 achieved a 49% response rate and 9.1 months median progression-free survival.

• Combination of vopimetostat/TNG462 with RAS inhibitors demonstrates strong preclinical synergy and early clinical activity, supporting chemo-sparing regimens.

• TNG908/TNG456 is in phase 1/2 for glioblastoma, with FDA Fast Track and Orphan Drug designations, and first patients recently enrolled.

Market opportunity and scientific rationale

• MTAP deletion is a common genetic alteration in several cancers, affecting 60,000 patients annually in the US, with high prevalence in pancreatic, lung, and glioblastoma.

• MTAP deletion confers sensitivity to PRMT5 inhibitors, creating a large development opportunity.

• PRMT5 inhibitors' efficacy relies on MTAP deletion; preclinical data do not support use in non-MTAP-deleted tumors.